Medindia

X

WNDM Files Q1 Results; Company Reports Record Revenue; Cash Position at All-Time High

Wednesday, May 18, 2011 General News J E 4
Advertisement

WOUND MANAGEMENT TECHNOLOGIES, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2011 and 2010

2011

2010

Cash flows from operating activities:

Net loss from continuing operations

$

(2,743,921)

$

(1,244,507)

Adjustments to reconcile net loss to net cash provided (used) in

operating activities:

     Depreciation and amortization

259,110

117,940

 Amortization of discounts and deferred costs

194,014

13,655

 Stock issued for debt related costs

405,580

-

 Stock issued as payment for services

112,000

70,050

 Loss on debt settlement

1,950,882

720,657

     Non-cash expenses

50,347

21,019

Changes in assets and liabilities:

    (Increase) decrease in accounts receivable

252,444

(2,435)

    (Increase) decrease in inventory

(51,893)

379

(Increase) decrease in accrued interest receivable - related parties

(15,690)

(15,820)

(Increase) decrease in accrued interest receivable

(33,750)

(22,125)

(Increase) decrease in prepaids and other assets

107,150

27,549

    Increase (decrease) in accrued royalties

(358,323)

2,125

    Increase (decrease) in accounts payable

(230,498)

(29,638)

Increase (decrease) in accrued liabilities

180,071

(746)

Increase (decrease) in accrued interest payable - related parties

12,165

50,437

Increase (decrease) in accrued interest payable

34,590

6,650

Net cash flows provided (used) in operating activities

124,278

(284,810)

Cash flows from investing activities:

Cash paid in acquisitions

-

(100,000)

Purchase of notes receivable - related parties

(2,231,658)

(103,950)

Proceeds from notes receivable - related parties

1,546,120

41,413

Net cash flows used in investing activities

(685,538)

(162,537)

Cash flows from financing activities:

Net change in overdraft

-

(4,363)

Proceeds from notes payable - related parties

61,500

512,587

Payments on notes payable - related parties

(952,268)

(7,050)

Proceeds from notes payable

2,060,000

102,500

Payments on notes payable

(537,000)

(153,775)

Proceeds from sale of stock

868,700

-

Proceeds from stock subscriptions payable

31,000

-

Net cash flows provided by financing activities

1,531,932

449,899

Increase in cash

970,672

2,552

Cash and cash equivalents, beginning of period

50,835

-

Cash and cash equivalents, end of period

$

1,021,507

$

2,552

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
HealthSouth Corporation Agrees to Sell its Six Lon...
S
Perrigo's Partner Synthon Receives FDA Tentative A...